INTRODUCTION

The search for specific diagnostic markers in psychiatry still has not provided that many clinically useful findings and that is especially true in the case of depression and schizophrenia.1-6 However, a quantitative test that would be useful in diagnosing and treatment of depression or schizophrenia has yet to be discovered.7

Serotonergic system has long been implicated in the pathogenesis of depression, while its proposed effects within the schizophrenic process are closely related to the major implicated pathway of dopamine.8-11 On these foundations, today’s most effective treatments for depression, and to a significant extent also for schizophrenia, affect serotonin system at different levels and targets, all of which have in common alteration of serotonin levels.11 As central serotonergic neurons are still inaccessible, blood platelets have been used for years as a peripheral model of neuronal serotonin dynamics. That is especially the case as in both the process of serotonin release and reuptake seems to be practically the same,12,13 although some of the more recent findings argue against such modelling.14 However, high blood serotonin concentration does not necessarily imply high platelet serotonin concentration, but in physiological conditions could directly relate to it.14,15

Among other factors that have been shown to influence platelet count and possibly serotonin concentration,14,16 we would like to highlight the age. Nowadays there are several lines of evidence that support that platelets from older subjects differ in their function and structure,18 along with higher sensitivity and an increased responsiveness to serotonin than platelets.
from subjects in their early twenties. Nevertheless, platelet serotonin content seems to decrease with age. This leads to the suggestion that platelet hyperactivity can cause an increased release of serotonin in plasma. Most studies in patients with depression did not report significant differences between serotonin concentration and age, nor did studies focusing on schizophrenia.

Available findings describe significantly lower platelet serotonin concentrations in depressive patients compared to healthy individuals, although there have been reports of non-significant differences or no differences at all. As far as the psychotic symptoms are concerned, platelet serotonin concentrations were reported to be higher in psychotic depressed patients compared to patients who were not psychotic. In suicidal depressive patients, compared to non-suicidal depressive patients and healthy controls, platelet serotonin concentrations have frequently been reported to be significantly lower. As far as the treatment is concerned, antidepressants have shown to significantly lower and normalize platelet serotonin concentrations. Also, a lower platelet serotonin could be a trait of depressive patients with metabolic syndrome. Based on some of the presented findings, there have been earlier propositions of baseline platelet serotonin concentration being used as a predictor of the antidepressant treatment response.

Studies on platelet serotonin in schizophrenia repeatedly reported significantly higher concentrations, especially in untreated patients in patients with predominantly positive symptoms or in patients with schizophrenia without significant depressive symptoms. Also, lower platelet serotonin concentrations have been observed in schizophrenic patients treated with neuroleptics and higher platelet serotonin concentration has been linked to a better response to olanzapine therapy in schizophrenic patients. Regarding patients with first psychoses, Marinko et al. and associates reported significantly lower platelet serotonin concentrations in suicidal than non-suicidal patients and healthy controls. In one direct comparison of depressive and schizophrenic patients, platelet serotonin concentrations were reported to be higher in those suffering from schizophrenia. Partially confirming and expanding on these findings, in our previous research we observed an association between lower platelet serotonin concentration and more severe depressive symptomatology in schizophrenic patients.

These findings indicate that the platelet serotonin concentrations might have a functional significance in pathophysiology and/or treatment of depression and schizophrenia, regardless significant differences between investigations. In this research we focused on two platelet variables, platelet count and platelet serotonin concentration, in an attempt to gain insight into the question if they could be used as a clinically useful diagnostic test in schizophrenia and/or depression.

METHODS

Participants

In total, 953 participants were enrolled in this research. The schizophrenia group consisted of 339 patients, while the depression group consisted of 329 patients. Control group consisted of 285 healthy participants who volunteered to participate in the research. The schizophrenia group included 221 males and 118 females, while the group of patients suffering from depression included 200 males and 129 females. Group of healthy individuals included 160 males and 125 females. Sociodemographic and clinical parameters of all included subjects are presented in Table 1. All subjects with depression and schizophrenia were inpatients. The inclusion criteria for this study were the diagnosis of depression or schizophrenia, using the DSM-5 criteria and the absence of any other psychiatric disorder. Inclusion criteria for the group of healthy volunteers were no personal history of any kind of mental illness and negative hereditary loading for mental illness. Participants with any use of psychoactive compounds including alcohol in their medical history were excluded from the study. Exclusion criteria also included any kind of somatic disorders. None of the patients included in this study had taken any psychotropic medication 30 or more days prior to the study, as it is well known that antidepressants alter platelet serotonin concentrations. However, it has also previously been shown that antipsychotic treatment is able to alter platelet serotonin concentrations. Furthermore, we were able to recruit such a relatively large sample of medication free patients due to the fact they did not adhere to psychopharmacological treatment. This issue is of major concern, as patients with depression and even more so patients with schizophrenia, indeed tend to poorly adhere to their treatment. That is especially an issue with antipsychotic medication, which usually results in increased symptom severity and more frequent hospital admissions.

Although they did not adhere to their treatment, prior to hospital admission majority of patients have been prescribed with an atypical antipsychotic and a minority with a typical antipsychotic medication. Informed consent was obtained from all included patients after a complete and extensive description of the study profile. The study was approved by Ethics Committee of the University Hospital Centre Sestre milosrdnice (EP-6820/13-18).

Medical examination and study design

The study included all patients that had been admitted for inpatient treatment with the diagnosis of schizophrenia or depression in the period from June 2014 to September 2019. All
patients with depression and schizophrenia presenting the above described exclusion criteria were excluded from the study. Structured clinical interview was performed by a psychiatrist, who made the diagnosis based on the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) criteria for schizophrenia. The severity of schizophrenia was assessed by the Positive and negative syndrome scale (PANSS). With Hamilton depression rating scale (HDRS) we assessed the severity of depression. Variables of disease features (number of episodes, duration of illness in years) were obtained from the structured clinical interview based on the Mini International Neuropsychiatric Interview (MINI) and were performed by a trained psychiatrist.

Biochemical measurements and preparation of platelet-rich plasma (PRP)

Blood samples were taken from patients for the analysis to determine platelet serotonin levels. Blood samples were taken from the cubital vein in one vacuumed eprouvette with EDTA anticoagulant for the determination of platelet serotonin in the morning, after 12 h of fasting and after a 30 minute pause. The platelet serotonin was determined with the enzyme-linked immunosorbent assay (ELISA) procedure using commercial reagents (DRG Diagnostics, Germany). In our laboratory, the value of the inter-assay CV was 6% for platelet serotonin.

The platelet number was determined on hematology analyzer (Beckman Coulter DxH 800, USA), with prior verifica-
tion of a blank sample. The PRP was prepared a maximum of 2 h after taking the blood sample. The PRP was obtained by centrifuging the sample at 200×g for 10 min at room temperature. The supernatant was separated and the number of platelets within was also determined. Platelets were then lysed by separating 200 µL PRP in 800 µL 0.9% sodium chloride solution and centrifuging the suspended cells at 4,500×g for 10 min at 4°C. After separation of the supernatant, 200 µL of redistilled water was added to the sediment containing platelets and the mixture was mechanically mixed on a vortex mixer to fully lyse the platelets. This prepared platelet lysate was stored at -20°C (for a maximum of three weeks). To determine the concentration of serotonin in the stored platelet lysate, the samples were thawed and centrifuged at 10,000×g for 2 min at room temperature.

**Statistical analyses**

Kolmogorov-Smirnov test was used to assess normal distribution for all measures and for each group. Sociodemographic and clinical characteristics of patients and healthy control subjects were compared in frequencies using the chi-square test and for continuous sociodemographic variables and platelet count and serotonin concentration using the independent samples t-test (comparison between two groups) or ANOVA (comparison between three groups). We performed linear regression analysis in order to test the predictions of symptom severity of schizophrenia and depression (PANSS and HDRS), number of episodes and overall illness duration for both disorders on platelet count and serotonin concentration. We also used linear regression analysis to test the predictions of patient’s age on total platelet count and serotonin concentration. Optimal sensitivity and specificity of the platelet serotonin concentration for the diagnosis of depression and schizophrenia were determined with the receiver operating characteristic (ROC) curve analysis and utilizing a nonparametric approach. The Youden index was calculated for each cut-off value as corresponding [(sensitivity+specificity)-1] to find the cut-off values that maximize discriminating power of the test. Alpha values were conservatively considered significant at less than 0.01. Statistical analyses were conducted using SPSS software (SPSS for Windows 20.0, IBM Corp., Armonk, NY, USA).

**RESULTS**

We established statistically significant differences between patients with depression and patients with schizophrenia and healthy individuals regarding several sociodemographic and clinical characteristics. However, there were no statistically significant differences among groups regarding age, total platelet count and serotonin concentration. Two groups consisting of patients with depression and schizophrenia did not statistically differ in terms of number of illness episodes and illness duration (Table 1).

In order to establish if age influences total platelet count, we performed linear regression analysis in which platelet count was a dependent variable and age (separately for all three groups) was a predictor variable. Linear regression analysis established that the variance of the dependent variable is explained by 0.1% (r²=0.001) in depression, 0.2% (r²=0.002) in schizophrenia and 0.3% (r²=0.003) in healthy individuals. Analysis of variance was performed as the next phase of linear regression. It did not reveal statistical significance of the model (F=0.278; p=0.598 in depression; F=0.514; p=0.474 in schizophrenia and F=0.786; p=0.376 in healthy individuals), which means that platelet count does not depend on age (Table 2).

Next step was to test if number of episodes and illness duration have an influence on the total platelet count. Therefore, we performed linear regression analysis in which platelet count was a dependent variable and number of episodes and illness duration (separately for groups with depression and schizophrenia) were predictor variables. Linear regression analysis established that the variance of the dependent variable is explained by 1.9% (r²=0.019) in depression and 1.6% (r²=0.016) in schizophrenia. Analysis of variance was performed as the next phase of linear regression. It did not reveal statistical significance (F=1.217; p=0.300 in depression; F=2.249; p=0.107 in schizophrenia), which means that platelet count does not depend on the two included predictor variables (Table 2).

And finally, we tested if clinical severity scores (HDRS and PANSS) have an influence on the total platelet count. Linear regression analysis was performed with platelet count as a dependent variable and clinical severity scores as predictor variables. In the end, variance of the dependent variable is explained by 2.6% (r²=0.026) of the HDRS score in depression and 1.7% (r²=0.017) of the PANSS score in schizophrenia. Analysis of variance was performed as the next phase of linear regression. It did reveal statistical significance (F=5.382; p=0.021 for HDRS and F=1.095; p=0.360 for PANSS), which means that platelet count does not depend on PANSS scores in schizophrenia, but it does on HDRS score in depression (Table 2).

Linear regression analyses were also performed in order to establish the influence of the same set of variables on platelet serotonin concentration. In the first step platelet serotonin concentration was the dependent variable and age (separately for all three groups) was a predictor variable. Linear regression analysis established that the variance of the dependent variable is explained by 1.5% (r²=0.015) in depression, 0.3% (r²=0.003) in schizophrenia and 1.8% (r²=0.018) in healthy individuals. Analysis of variance was performed as the next phase
of linear regression. It did reveal statistical significance in patients with depression (F=5.038; p=0.025) and healthy individuals (F=4.464; p=0.036), but not in patients with schizophrenia (F=1.080; p=0.300), which means that platelet serotonin concentration does depend on age in patients with depression and healthy individuals (Table 3).

Next step was to test if number of episodes and illness duration have an influence on platelet serotonin concentration. In this linear regression analysis number of episodes and illness duration (separately for groups with depression and schizophrenia) were predictor variables. Linear regression analysis established that the variance of the dependent variable is ex-

Table 2. Predictive values of age, illness duration, episode number and clinical severity scores (HDRS and PANSS) on total platelet count

| Platelet count | Unstandardized coefficients | Standardized coefficients | t | p | 95.0% confidence interval for B |
|----------------|-----------------------------|---------------------------|---|---|-------------------------------|
|                | B                           | Std. error                | β |     | Lower bound | Upper bound |
| Age            |                             |                           |   |     |               |             |
| Depression     | 0.165                       | 0.314                     | 0.037 | 0.528 | 0.598 | -0.453 | 0.784 |
| Schizophrenia  | 0.221                       | 0.309                     | 0.043 | 0.717 | 0.474 | -0.387 | 0.830 |
| Healthy        | -0.244                      | 0.276                     | -0.059 | -0.886 | 0.376 | -0.788 | 0.299 |
| Depression     |                             |                           |   |     |               |             |
| Episode number | 0.307                       | 2.127                     | 0.013 | 0.144 | 0.885 | -3.902 | 4.516 |
| Illness duration | -5.225                  | 3.349                     | -0.138 | -1.560 | 0.121 | -11.853 | 1.404 |
| HDRS           | 1.675                       | 0.722                     | 0.161 | 2.320 | 0.021 | 0.251 | 3.098 |
| Schizophrenia  |                             |                           |   |     |               |             |
| Episode number | -2.006                      | 1.168                     | -0.104 | -1.718 | 0.087 | -4.306 | 0.293 |
| Illness duration | -5.659                | 4.827                     | -0.071 | -1.172 | 0.242 | -15.162 | 3.844 |
| PANSS total    | 2.635                       | 1.961                     | 0.222 | 1.344 | 0.180 | -1.226 | 6.497 |
| PANSS positive | 2.001                       | 2.090                     | -0.170 | -0.957 | 0.339 | -6.117 | 2.116 |
| PANSS negative | -1.809                      | 2.313                     | -0.138 | -0.782 | 0.435 | -6.364 | 2.747 |
| PANSS general  | -3.585                      | 2.065                     | -0.545 | -1.736 | 0.084 | -7.652 | 0.481 |

HDRS: Hamilton Depression Rating Scale, PANSS: Positive and Negative Syndrome Scale

Table 3. Predictive values of age, illness duration, episode number and clinical severity scores (HDRS and PANSS) on platelet serotonin concentration

| Platelet serotonin concentration | Unstandardized coefficients | Standardized coefficients | t | p | 95.0% confidence interval for B |
|----------------------------------|-----------------------------|---------------------------|---|---|-------------------------------|
|                                  | B                           | Std. error                | β |     | Lower bound | Upper bound |
| Age                              |                             |                           |   |     |               |             |
| Depression                       | -2.912                      | 1.297                     | -0.123 | -2.244 | 0.025 | -5.465 | -0.360 |
| Schizophrenia                    | -1.755                      | 1.690                     | -0.057 | -1.039 | 0.300 | -5.079 | 1.568 |
| Healthy                          | -4.178                      | 1.977                     | -0.136 | -2.113 | 0.036 | -8.074 | -0.283 |
| Depression                       |                             |                           |   |     |               |             |
| Episode number                   | 0.228                       | 10.388                    | 0.002 | 0.022 | 0.982 | -20.306 | 20.763 |
| Illness duration                 | 9.613                       | 16.360                    | 0.049 | 0.588 | 0.558 | -22.728 | 41.954 |
| HDRS                             | 3.333                       | 3.481                     | 0.064 | 0.957 | 0.339 | -3.527 | 10.193 |
| Schizophrenia                    |                             |                           |   |     |               |             |
| Episode number                   | -0.357                      | 6.882                     | -0.003 | -0.052 | 0.959 | -13.900 | 13.186 |
| Illness duration                 | -62.869                     | 22.306                    | -0.160 | -2.819 | 0.005 | -106.763 | -18.975 |
| PANSS total                      | -3.718                      | 11.638                    | -0.168 | -0.320 | 0.750 | -26.626 | 19.189 |
| PANSS positive                   | -2.148                      | 12.354                    | -0.030 | -0.174 | 0.862 | -26.465 | 22.169 |
| PANSS negative                   | 6.377                       | 13.642                    | 0.079 | 0.467 | 0.641 | -20.474 | 33.229 |
| PANSS general                    | -3.837                      | 12.223                    | -0.097 | -0.314 | 0.754 | -27.897 | 20.222 |

HDRS: Hamilton Depression Rating Scale, PANSS: Positive and Negative Syndrome Scale
explained by 0.2% ($r^2=0.002$) in depression and 2.6% ($r^2=0.026$) in schizophrenia. Analysis of variance revealed statistical significance for the sample of patients with schizophrenia ($F=3.972; p=0.020$), but not for the sample of patients with depression ($F=0.174; p=0.840$), which means that platelet serotonin concentration does depend on the illness duration variable in patients with schizophrenia (Table 3).

As the last step we tested if clinical severity scores (HDRS and PANSS) have an influence on the platelet serotonin concentration. Clinical severity scores were predictor variables. Variance of the dependent variable is explained by 0.4% ($r^2=0.004$) of HDRS score in depression and 5.2% ($r^2=0.052$) of PANSS score in schizophrenia. Analysis of variance revealed statistical significance of the model with platelet serotonin concentration as a dependent variable and PANSS score as a predictor variable ($F=3.878; p=0.004$), but not when HDRS was a predictor variable ($F=0.917; p=0.339$), which means that platelet serotonin concentration does not depend on HDRS score in depression, but it does on PANSS score in schizophrenia. However, when analysing PANSS subscale scores and even total PANSS score independently, that significance was not present (Table 3).

ROC analysis did not establish significant diagnostic value of platelet serotonin concentration when comparing patients with depression and healthy individuals. The area under the curve (AUC) was 0.517 with a 95% confidence interval (0.472–0.563; $p=0.455$). ROC analysis also failed to demonstrate the diagnostic value of platelet serotonin concentration when comparing patients with depression and schizophrenia. The area under the curve (AUC) was 0.515 with a 95% confidence interval (0.471–0.558; $p=0.514$). Finally, ROC analysis did not establish significant diagnostic value of platelet serotonin concentration when comparing patients with schizophrenia and healthy individuals. The area under the curve (AUC) was 0.510 with a 95% confidence interval (0.465–0.556; $p=0.655$). We did not include graphical presentations due to non-significant findings of the ROC analysis.

**DISCUSSION**

This study included 953 participants, which is to the best of our knowledge largest investigation of platelet serotonin count and concentration in depression and schizophrenia. There were no differences in ratio of males to females when comparing three groups of participants, and majority of patients (compared to healthy individuals) were of lower educational status, unemployed or retired. All of these findings reflect our understanding of the burden that psychiatric disorders impose on patients, especially those suffering from schizophrenia. When it comes to their marital status, patients with depression did not statistically differ from healthy individuals, but both of those groups were significantly more often married than patients with schizophrenia.

The groups did not differ in age, platelet count and platelet serotonin concentration. When it comes to comparing patients with depression and healthy individuals, previously there have been similar findings, but also of lower platelet serotonin concentrations in depressive patients. On the other hand, majority of research on platelet serotonin in schizophrenia repeatedly reported significantly higher concentrations, except in a subgroup of patients with schizophrenia and significant depressive symptoms and suicidal first episode psychoses. Although our results did not replicate it, in one previous comparison of depressive and schizophrenic patients, platelet serotonin concentrations were higher in patients with schizophrenia. In order to test for associations between clinical severity score (HDRS and PANSS) and platelet count and serotonin concentration we also performed regression analyses which revealed the association between HDRS score and platelet count in depression (but not platelet serotonin concentration). Therefore, we had to conclude that symptomatology of schizophrenia (quantified by four PANSS scores) was not correlated with platelet count nor platelet serotonin concentration, which is a replication of our previous findings.

Previous reports in healthy individuals established that age was inversely associated with platelet count and platelet serotonin content. Although we did not find a significant association regarding platelet count (in all three groups) we did replicate the association between platelet serotonin concentration and age in healthy individuals. Somewhat surprisingly, the same positive association was also present in patients with depression, which is contrast with previously reported non-significant findings, although on smaller samples. One thing to keep in mind when interpreting those findings is the possibility of false positive results due to antidepressant treatment, which is known to alter platelet serotonin concentrations.

In this sample, patients were off their antidepressant and other medications for at least a month prior to study enrolment, which is sufficient to rule them out as a confounding variable. Similarly to previous reports, in our sample platelet serotonin concentration in schizophrenia was not associated with age.

Two groups of patients did not differ regarding number of episodes and overall illness duration. However, when examining for a possible correlation between number of episodes and overall illness duration on platelet count and serotonin concentration, we established a single positive correlation, the one between overall illness duration and platelet serotonin concentration in schizophrenia. Therefore, in patients with schizophrenia there is a significant decline of platelet serotonin concentration (in an otherwise not significantly declining platelet serotonin concentration in depression).
In conclusion, this study provides first evidence of differing platelet serotonin concentrations in schizophrenia regarding the duration of the illness in a manner that duration seems to be inversely correlated to platelet serotonin concentration. Interestingly, age was not correlated with platelet serotonin concentration in schizophrenia, suggesting that illness duration solely influences platelet serotonin homeostasis and is quite possibly a trait of schizophrenia duration. Combined with age wise significant findings in patients with depression and healthy individuals, this finding could be specific to schizophrenia.

In a platelet model such as this, intracellular serotonin depends also on several other factors, which were not investigated at this point. Future studies should therefore include all relevant elements of serotonin homeostasis across the human life span in an attempt to clarify serotonin dynamics in ageing of psychiatric patients, which might provide an answer to relatively ambiguous findings regarding platelet serotonin concentrations in researches performed so far.

Acknowledgments

This research was funded from the fund for scientific research of University of Zagreb’s School of Dental Medicine.

The authors are indebted to all of the physicians, nurses, and study coordinators who cared for the patients and who kindly provided the data necessary for our analysis.

Conflicts of Interest

The authors have no potential conflicts of interest to disclose.

Author Contributions

Conceptualization: Dalibor Karlović. Data curation: Vjekoslav Peitl, Biserka Getaldić-Śvarc. Formal analysis: Vjekoslav Peitl. Investigation: Vjekoslav Peitl, Biserka Getaldić-Śvarc, Dalibor Karlović. Methodology: Biserka Getaldić-Śvarc, Dalibor Karlović. Resources: Dalibor Karlović. Software: Dalibor Karlović. Supervision: Vjekoslav Peitl, Biserka Getaldić-Śvarc, Dalibor Karlović. Validation: Vjekoslav Peitl, Dalibor Karlović. Writing—original draft: Vjekoslav Peitl, Biserka Getaldić-Śvarc, Dalibor Karlović. Writing—review & editing: Vjekoslav Peitl, Dalibor Karlović.

ORCID iDs

Vjekoslav Peitl https://orcid.org/0000-0003-4163-6411
Biserka Getaldić-Śvarc https://orcid.org/0000-0002-6809-3181
Dalibor Karlović https://orcid.org/0000-0001-6538-7240

REFERENCES

1. Galvez-Contreras AY, Campos-Ordonez T, Lopez-Virgen V, Gomez-Plascencia J, Ramos-Zuniga R, Gonzalez-Perez O. Growth factors as clinical biomarkers of prognosis and diagnosis in psychiatric disorders. Cytokine Growth Factor Rev 2016;32:85-96.
2. Gururajan A, Clarke G, Dinan TG, Cryan JF. Molecular biomarkers of depression. Neurosci Biobehav Rev 2016;64:101-133.
3. Lai CY, Scarr E, Udsalwa M, Everall I, Chen WJ, Dean B. Biomarkers in schizophrenia: a focus on blood based diagnostics and theranostics. World J Psychiatry 2016;6:102-117.
4. Okazaki S, Boku S, Otsuka I, Mouri K, Aoyama S, Shirouka K, et al. The cell cycle-related genes as biomarkers for schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2016;70:85-91.
5. Karlović D, Serretti A, Vrkić N, Martinac M, Marčinko D. Serum concentrations of CRP, IL-6, TNF-α, and cortisol in major depressive disorder with melancholic or atypical features. Psychiatry Res 2012;198:74-80.
6. Silic A, Karlović D, Serretti A. Increased inflammation and lower platelet 5-HT in depression with metabolic syndrome. J Affect Disord 2012;141:72-78.
7. Lakhan SE, Vieira K, Hamlat E. Biomarkers in psychiatry: drawbacks and potential for misuse. Int Arch Med 2010;3:1.
8. Maes M, Meltzer HY. The Serotonin Hypothesis of Major Depression. In: Bloom FE, Kuper DJ, Editors. Psychopharmacology: The fourth Generation of Progress. New York: Raven Press, 1995, p.933-944.
9. Abi-Dargham A, Laruelle M, Aghajanian GK, Charney D, Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiatry Clin Neurosci 1997;9:1-17.
10. Jayett DC, Laruelle M. Neurochemical Theories. In: Lieberman JA, Scott Stroup T, Perkins DO, Editors. Textbook of Schizophrenia. Arlington: American Psychiatric Publishing Inc., 2006, p.85-116.
11. Lopez-Munoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 2009;15:1563-1586.
12. Stahl SM. Platelets as Pharmacological Models for the Receptors and
Platelet Serotonin Concentration in MDD and SCH

Biochemistry of Monoaminergic Neurons. In: Longenecker GL, Editor. Platelets: Physiology and Pharmacology. New York: Academic Press, 1985, p.307-340.

Muck-Seler D, Pivac N, Mustapic M, Crnecvic Z, Jakovljevic M, Sagud M. Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women. Psychiatry Res 2004;127:217-226.

Balija M, Bordukalo-Niksic T, Mokrovic G, Barovic M, Cinc-Sain L, Jernej B. Serotonin level and serotonin uptake in human platelets: a variable interrelation under marked physiological influences. Clin Chim Acta 2011;412:299-304.

Austen MC, Bradley CC, Mann JJ, Blakely RD. Expression of serotonin transporter messenger RNA in the human brain. J Neurochem 1994; 62:2362-2367.

Mercado CP, Klic F. Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels. Mol Interv 2010;10:231-241.

Hervig TA, Farstad M, Vollset SE. Endogenous serotonin in human blood platelets: factors that may influence reference values. Platelets 1996;7:47-52.

Le Blanc J, Lordkipanidzé M. Platelet function in aging. Front Cardiovasc Med 2019;6:109.

Gleerup G, Winther K. The effect of ageing on human platelet sensitivity to serotonin. Eur J Clin Invest 1988;18:504-506.

Flachaire E, Beney C, Berthier A, Salandre J, Quincy C, Renaud B. Determination of reference values for serotonin concentration in platelets of healthy newborns, children, adults, and elderly subjects by HPLC with electrochemical detection. Clin Chem 1990;36:2117-2120.

Sagud M, Nikolac Perkovic M, Vuksan-Cusa B, Maravic A, Svol Strac D, Mihaljevic Peles A, et al. A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment. Psychopharmacology (Berl) 2016;233:3259-3267.

Muck-Seler D, Pivac N, Jakovljevic M. Sex differences, season of birth and platelet 5-HT levels in schizophrenic patients. J Neural Transm (Vienna) 1999;106:337-347.

Kaneda Y, Fujii A, Nagamine I. Platelet serotonin concentrations in medicated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:983-992.

Ruljanic N, Mihanovic M, Cepelak I, Bakliza A, Curkovic KD. Platelet serotonin and magnesium concentrations in suicidal and non-suicidal depressed patients. Magnes Res 2013;26:9-17.

Moreno J, Campos MG, Lara C, López G, Pavón I, Hernández ME, et al. Tryptophan and serotonin in blood and platelets of depressed patients: effect of an antidepressant treatment. Sahed Med 2006;29:1-8.

Mück-Seler D, Jakovljevic M, Pivac N. Platelet 5-HT concentrations and suicidal behaviour in recurrent major depression. J Affect Disord 1996;39:73-80.

Braunig P, Rao ML, Fimmers R. Blood serotonin levels in suicidal schizophrenic patients. Acta Psychiatr Scand 1989;79:186-189.

van Kempen GM, Notten P, Hengeveld MW. Repeated measures of platelet MAO activity and 5-HT in a group of suicidal women. Biol Psychiatry 1992;31:529-530.

Pivac N, Jakovljevic M, Mück-Seler D, Brzovic Z. Hypothalamic-pituitary-adrenal axis function and platelet serotonin concentrations in depressed patients. Psychiatry Res 1997;73:123-132.

Rao ML, Hawelkek B, Popasotitopoulos A, Deister A, Frawhuet C. Upregulation of the platelet Serotonin2A receptor and low blood serotonin in suicidal psychiatric patients. Neuropsychobiology 1998;38:84-89.

Alvarez JC, Cremniter D, Lesieur P, Gregoire A, Gilton A, Macquin-Mavier I, et al. Low blood cholesterol and low platelet serotonin levels in violent suicide attempters. Biol Psychiatry 1999;45:1066-1069.

Anderson GM. Peripheral and central neurochemical effects of the selective serotonin reuptake inhibitors (SSRIs) in humans and nonhuman primates: assessing bioeffect and mechanisms of action. Int J Dev Neurosci 2006;22:397-404.

Muck-Seler D, Pivac N, Sagud M, Mustapic M, Jakovljevic M. The Effects of serotonin uptake inhibitors on Platelet Serotonin: From Basic to Clinical Research. In: Shirley AC, Editor. Trends in Serotonin Uptake Inhibitors Research. New York: Nova Science Publishers Inc., 2005, p.29-39.

Maurer-Spurej E, Pittendreigh C, Misri S. Platelet serotonin levels support depression scores for women with postpartum depression. J Psychiatry Neurosci 2007;32:22-29.

Zhuang X, Xu H, Fang Z, Xu C, Xue C, Hong X. Platelet serotonin and serotonin transporter as peripheral surrogates in depression and anxiety patients. Eur J Pharmacol 2018;834:213-220.

Figuera G, Pérez V, San Martino O, Alvarez E, Artigas F. Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression. Grupo de Trastornos Afectivos. Biol Psychiatry 1999;46:518-524.

Mück-Seler D, Pivac N, Sagud M, Jakovljevic M, Mihaljevic-Peles A. The effects of paroxetine and tianeptin on peripheral biochemical markers in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1235-1243.

Mészáros Z, Borcsiczyk D, Máté M, Tarczi J, Tekes K, Magyar K. MAO inhibition side effects of neuroleptics and platelet serotonin content in schizophrenic patients. J Neural Transm 1998;52(Suppl):79-85.

Ertugrul A, Ucar G, Basar K, Yabanoglu S, Ulug R. Influence of clozapine on platelet serotonin, monoamine oxidase and plasma serotonin levels. Psychiatry Res 2007;149:49-57.

Muck-Seler D, Jakovljevic M, Deanovic Z. Platelet serotonin subtypes of schizophrenia and unipolar depression. Psychiatry Res 1991;38:105-113.

Petit V, Vidrigh B, Karlović Z, Getaldič B, Petit M, Karlović D. Platelet serotonin concentration and depressive symptoms in patients with schizophrenia. Psychiatry Res 2016;239:105-110.

Brusov OS, Faktor MI, Zlobina GP, Dupin AM, Katasonov AB, Kartseneva NK, et al. Parameters of platelet serotonin system in patients with schizophrenia treated with olanzapine: a search for the serotonergic predictors of therapeutic efficacy. Zh Nevrol Psihiatr Im S S Korsakova 2005;105:27-34.

Marcinko D, Pivac N, Martinac M, Jakovljevic M, Mihaljevic-Peles A, Mück-Seler D. Platelet serotonin and serum cholesterol concentrations in suicidal and non-suicidal male patients with a first episode of psychosis. Psychiatry Res 2007;150:105-108.

van der Heijden FM, Tuinier S, Fekkes D, Sijben AE, Kahn RS, Verhoeven WM. Atypical antipsychotics and the relevance of glutamate and serotonin. Eur Neuropsychopharmacol 2004;14:259-265.

Sacchetti E, Vita A. Poor Adherence to Antipsychotic Medication in People with Schizophrenia: Diffusion, Consequences and Contributing Factors. In: Sacchetti E, Vita A, Editors. Adherence to Antipsychotics in Schizophrenia. Milan: Springer-Verlag, 2014, p.1-29.

Kay SR, Fisbein A, Opler A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.

Helund JL, Vieweg BW. The Hamilton rating scale for depression: a comprehensive review. J Oper Psychiatry 1978;10:149-165.

Sheehan DV, Lecrubier Y, Sheehan KH, Janavs J, Weiller E, Yarnold PR, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):34-57.

Livingston JD, Boyd JE. Correlates and consequences of internalized stigma for people living with mental illness: a systematic review and meta-analysis. Soc Sci Med 2010;71:2150-2161.

Queenwood BB, Geyer MA, Halberstadt AL. Serotonin and Schizophrenia. In: Müller C, Jacobs B, Editors. Handbook of Behavioral Neurobiology of Serotonin. London, UK: Elsevier BV, 2010, p.585-620.

Eggers AE. A serotonin hypothesis of schizophrenia. Med Hypotheses 2013;80:791-794.

Kim SW, Kim SJ, Mun JW, Bae KY, Kim JM, Kim SY, et al. Psychosocial factors contributing to suicidal ideation in hospitalized schizophrenia patients in Korea. Psychiatry Investig 2010;7:79-85.